Dr. Anthony Mutsaers

Meet Dr. Anthony Mutsaers

DVM, PhD, Diplomate ACVIM (Oncology)

Profile(s): University of Guelph Experts, Department of Biomedical Sciences, Department of Clinical Studies, Institution for Comparative Cander Investigation

Keywords: Comparative oncology, osteosarcoma, metronomic chemotherapy, tumour angiogenesis, tumour stress responses, tumour metabolism 

Current Positions:

  • Associate Professor – Cross-appointed: Departments of Biological Sciences and Clinical Studies, Ontario Veterinary College, University of Guelph)
  • Medical Oncology Team Clinician – Health Sciences Centre, Ontario Veterinary College, University of Guelph

Education and Employment Background:

  • Doctor of Veterinary Medicine (Ontario Veterinary College, Guelph, ON) 
  • PhD – Medical Biophysics (University of Toronto, Toronto, ON)  
  • Residency – Comparative Oncology (Perdue University, West Lafayette, IN) 
  • Diplomate ACVIM – Oncology 
  • Post-doctoral fellowship – Osteosarcoma; Stem Cell Regulation Unit (St Vincent’s Institute of Medical Research, Melbourne, Australia) 

Research Themes & Interests:

  • Comparative oncology
  • Osteosarcoma
  • Metronomic chemotherapy and tumour angiogenesis
  • Cancer metabolism and stress responses
  • Radiation and chemotherapy sensitization
  • Biomarkers for clinical application of targeted oncology drugs

Select Publications:

  • Aborig M, Malik PRV, Nambiar S, Chelle P, Darko J, Mutsaers A, Edginton AN, Fleck A, Osei E, Wettig S.  Biodistribution and physiologically-based pharmacokinetic modeling of gold nanoparticles in mice with interspecies extrapolation.  Pharmaceutics 2019 Apr 12;11(4). pii: E179. 
  • Poon AC, Inkol JM, Luu AK, Mutsaers AJ.  Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.  J Vet Intern Med 2019 Mar;33(2):800-811. 
  • Hoddinott K, Oblak ML, Wood GA, Boston S, Mutsaers AJ.  Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells.  Can J Vet Res 2019 Jan;83(1):3-10. 
  • Luu AK, Schott CR, Jones R, Poon AC, Golding B, Hamed R, Deheshi B, Mutsaers A, Wood GA, Viloria-Petit AM.  An evaluation of TAZ and YAP crosstalk with TGFb signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.  BMC Vet Res 2018 Nov 26;14(1):365. 
  • Schott CR, Ludwig L, Mutsaers AJ, Foster RA, Wood GA.  The autophagy inhibitor spautin-1, either alone or combined with doxorubicin, decreases cell survival and colony formation in canine appendicular osteosarcoma cells.  PLoS One 2018 Oct 29;13(10):e0206427. 
  • Matsuyama A, Schott CR, Wood GA, Richardson D, Woods JP, Mutsaers AJ.  Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy.  J Am Vet Med Assoc 2018 Jun 1;252(11):1377-1383. 
  • Asthana R, Oblak ML, Singh A, Mutsaers AJ.  In vitro evaluation of a simulated pneumoperitoneum environment using carbon dioxide on canine transitional cell carcinoma.  Vet Surg 2018 Apr;47(3):412-420. 
  • Walia MK, Castillo-Tandazo W, Mutsaers AJ, Martin TJ, Walkley CR.  Murine models of osteosarcoma: a piece of the translational puzzle.  J Cell Biochem 2018 Jun;119(6):4241-4250. 
  • Kim C, Matsuyama A, Mutsaers AJ, Woods JP.  Retrospective evaluation of toceranib (palladia) treatment for canine metastatic appendicular osteosarcoma.  Can Vet J 2017 Oct;58(10):1059-1064. 
  • Matsuyama A, Poirier VJ, Mantovani F, Foster RA, Mutsaers AJ.  Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma.  J Am Anim Hosp Assoc 2017 Nov/Dec;53(6):304-312. 
  • Mould RC, AuYeung AWK, vanVloten JP, Susta L, Mutsaers AJ, Petrik JJ, Wood GA, Wootton SK, Karimi K, Bridle BW.  Enhancing immune responses to cancer vaccines using multi-site injections.  Sci Rep 2017 Aug 16;(7)1:8322. 
  • Matsuyama A, Woods JP, Mutsaers AJ.  Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer.  Can Vet J 2017 Jan;58(1):51-55
  • Calvalido J, Wood GA, Mutsaers AJ, Wood D, Sears W, Woods JP.  Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs.  Vet Immunol Immunopathol 2016 Dec;182:106-114. 
  • Asling J, Morrison J, Mutsaers AJ.  Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy.  Cell Stress Chaperones 2016 Nov;21(6):1065-1076. 
  • Mantovani FB, Morrison JA, Mutsaers AJ.  Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.  BMC Vet Res 2016 May 31;12:82. 
  • Uluckan O, Segaliny A, Botter S, Santiago JM, Mutsaers AJ.  Preclinical mouse models of osteosarcoma.  Bonekey Rep 2015 May 6;4:670. 
  • Gupte A, Baker EK, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, Karlstrom A, Mutsaers AJ, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer MA, Simpson KJ, Walkley CR.  Systematic screening identifies dual PI3k and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma.  Clin Cancer Res 2015 Jul 15;21(14):3216-29. 
  • Ng AJ, Walia MK, Smeets MF, Mutsaers AJ, Sims NA, Purton LE, Walsh NC, Martin TJ, Walkley CR. The DNA helicase recql4 is required for normal osteoblast expansion and osteosarcoma formation. PLoS Genet 2015 Apr 10;11(4):e1005160. 
  • Mutsaers AJ, Walkley CR.  Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?  Bone 2014;62:56-63. 
  • Mutsaers AJ, Ng AJM, Baker EK, Russell MR, Chalk AM, Wall M, Liddicoat BJJ, Ho PWM, Slavin JL, Goriada A, Martin TJ, Purton LE, Dickins RA, Walkley CR. Modeling distinct osteosarcoma subtypes in vivo using cre:lox and lineage restricted transgenic shRNA. Bone 2013;55(1):166-178. 
  • Ng AJM, Mutsaers AJ, Baker EK, Walkley CR.  Genetically engineered mouse models and human osteosarcoma.  Clin Sarcoma Res 2012;2(1):19. 
  • Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim A-C, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, Furfine ES.  Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.  mAbs 2010; 2(2):199-208. 
  • Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JML, Wu Y, Witte L, Berry S, Moore M, Kerbel RS.  Dose-dependent increases in TGFa and other ligands act as pharmacodynamic markers for optimal biologic dosing of cetuximab and are tumor independent.  Clin Cancer Res 2009; 15(7):2397-2405. 
  • Mutsaers AJ.  Metronomic Chemotherapy.   Topics in Companion Animal Medicine (Oncology) 2009; 24(3):137-143. 
  • Ebos JML, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS.  Vascular endothelial growth factor-mediated decrease in soluble vascular growth factor receptor-2 levels as a surrogate biomarker for tumor growth.  Cancer Res 2008; 68(2):521-529. 
  • Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS.  Multiple circulating proangiogenic factors induced by sunitinib maleate are tumor-independent and correlate with anti-tumor efficacy.  Proc Natl Acad Sci USA 2007; 104(43):17069-17074. 
  • Mutsaers AJ, Mohammed SI, DeNicola DB, Snyder PW, Glickman NW, Bennett PF, deGortari AE, Bonney PL, Knapp DW. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally-occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins, Leukot Essent Fatty Acids 2005; 72(3):181-186. 
  • Langova, V, Straw R, Mutsaers A, Thamm D.  Treatment of canine osteosarcoma with surgery, carboplatin, doxorubicin and piroxicam.  Aust Vet Pract 2004; 34(3):98-102. 
  • Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, DeGortari AE, Schlittler DL, Coffman KT, Bonney PL, Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003; 2(2):183-188. 
  • PubMed Compilation for Dr. Mutsaers: Link Out


Email: mutsaers@uoguelph.ca
Phone: (519) 824-4120 ext. 54068
Office: Biomed 3644 

Ontario Veterinary College
University of Guelph
50 Stone Road E.,
Guelph, ON, Canada, N1G 2W1